Get started
Author

Alfonso Berrocal

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
2020 · Carmen Balana, Maria Angeles Vaz, et al. · Neuro-Oncology · 106
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
2025 · Theresa Medina, Jason A. Chesney, et al. · Journal of Clinical Oncology · 88
PDF
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
2023 · Sarah A. Weiss, Mario Sznol, et al. · Clinical Cancer Research · 82
PDF
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
2007 · J Carles, E Esteban, et al. · Annals of Oncology · 58
PDF
Extended-schedule dose-dense temozolomide in refractory gliomas
2009 · GENOM Cooperative Group, A. Berrocal, et al. · Journal of Neuro-Oncology · 57
PDF
Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.
2014 · Jose Maria Piulats Rodriguez, Maria Ochoa de Olza, et al. · Journal of Clinical Oncology · 56
Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients
2019 · Anna Estival, Carolina Sanz, et al. · Scientific Reports · 40
PDF
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
2020 · M. Majem, E. García-Martínez, et al. · Clinical & Translational Oncology · 37
Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC)
2006 · R. Hitt, J. Grau, et al. · Journal of Clinical Oncology · 36
Melanoma and immunotherapy bridge 2015: Naples, Italy. 1–5 December 2015
2016 · Vashisht G. Y. Nanda, Weiyi Peng, et al. · Journal of Translational Medicine · 23
PDF
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study
2005 · Emilio Fonseca, Juan José Grau, et al. · European Journal of Cancer · 22
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
2016 · Elvira del Barco Morillo, Ricard Mesía, et al. · Oral Oncology · 17
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
2015 · J. M. Sepúlveda, C. Belda-Iniesta, et al. · Clinical & Translational Oncology · 16
Abstract LB198: A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
2023 · Oliver Bechter, Carmen Loquai, et al. · Cancer Research · 14
Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability.
2005 · Carlos Camps, Cristina Caballero, et al. · PubMed · 12
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors
2025 · Oliver Bechter, Carmen Loquai, et al. · Clinical Cancer Research · 11
826P Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial
2022 · I. Marquez-Rodas, A.M. Arance Fernandez, et al. · Annals of Oncology · 9
961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy
2021 · Iván Márquez Rodas, Philippe Saiag, et al. · Journal for ImmunoTherapy of Cancer · 9
PDF
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy
2021 · Sarah Weiss, Mario Sznol, et al. · Journal for ImmunoTherapy of Cancer · 8
PDF
Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
2016 · Matteo Carlino, Antoni Ribas, et al. · Cancer Research · 8
Phase II study of extended schedule temozolomide in refractory gliomas
2006 · A. Berrocal, P. Perez-Segura, et al. · Journal of Clinical Oncology · 8
Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases
2019 · Amaya B. Fernandez-Diaz, Adrian García-Medina, et al. · Melanoma Research · 7
Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study
2022 · Iván Márquez-Rodas, Caroline Dutriaux, et al. · Cancer Research · 6
Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor
2022 · Sanjeev Deva, Jacek Mackiewicz, et al. · Cancer Research · 4
1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
2021 · A.K.S. Salama, V. Cheshuk, et al. · Annals of Oncology · 4
PDF
Works count: 85
Citation count: 765
H-index: 14
I10-index: 16
Year
Topic
Type